A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COUGH-2; PN030
- Sponsors Merck Sharp & Dohme
- 09 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 22 May 2019 Rationale and Design was presented at the 115th International Conference of the American Thoracic Society.
- 08 Nov 2018 Planned End Date changed from 4 Jan 2021 to 8 Jan 2021.